GlassScriptPhysician profile
Aaron M Miller
NPI 1912936642
$4,099.72
in general payments reported to CMS, 2019-2025
25 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $70.82 · 2021: $309 · 2022: $300 · 2023: $293 · 2024: $2,711 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $732.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leadiant Biosciences, INC. | $2,500.00 | 2024 | |
| Abbvie INC. | $197.13 | 2023-2025 | |
| Pacira Pharmaceuticals Incorporated | $187.14 | 2022 | |
| Horizon Therapeutics Plc | $184.83 | 2021-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $151.34 | 2021 | |
| Amgen INC. | $92.76 | 2024-2025 | Tepezza |
| Coopervision INC. | $90.79 | 2019 | |
| Sun Pharmaceutical Industries INC. | $80.06 | 2020-2024 | Cequa |
| Rxsight INC | $60.41 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Genzyme Corporation | $59.77 | 2019-2020 | |
| Biotissue Holdings INC. | $50.00 | 2024 | |
| Carl Zeiss Meditec, INC. | $48.16 | 2019 | |
| Alcon Vision LLC | $46.85 | 2025 | Tryptyr, Rocklatan |
| Thea Pharma INC. | $44.44 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $41.18 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $39.05 | 2022 | |
| Eyevance Pharmaceuticals LLC | $38.58 | 2021 | |
| Kala Pharmaceuticals, INC. | $33.77 | 2022 | |
| Dompe US, INC. | $32.54 | 2024 | Oxervate |
| Genentech USA, INC. | $25.53 | 2023 | Vabysmo |
| Glaukos Corporation | $21.93 | 2021 | |
| Celularity INC. | $19.72 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $17.57 | 2022 | |
| Astellas Pharma US INC | $16.77 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.